KR102598775B1 - Ｒｏｒ­감마 조절제 - Google Patents

Ｒｏｒ­감마 조절제 Download PDF

Info

Publication number
KR102598775B1
KR102598775B1 KR1020197015082A KR20197015082A KR102598775B1 KR 102598775 B1 KR102598775 B1 KR 102598775B1 KR 1020197015082 A KR1020197015082 A KR 1020197015082A KR 20197015082 A KR20197015082 A KR 20197015082A KR 102598775 B1 KR102598775 B1 KR 102598775B1
Authority
KR
South Korea
Prior art keywords
formula
compounds
alkyl
delete delete
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197015082A
Other languages
English (en)
Korean (ko)
Other versions
KR20190096979A (ko
Inventor
라주 모한
존 누스
제이슨 해리스
Original Assignee
에스칼리에 바이오사이언시스, 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스칼리에 바이오사이언시스, 비브이 filed Critical 에스칼리에 바이오사이언시스, 비브이
Publication of KR20190096979A publication Critical patent/KR20190096979A/ko
Application granted granted Critical
Publication of KR102598775B1 publication Critical patent/KR102598775B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
  • Details Of Television Scanning (AREA)
KR1020197015082A 2016-10-27 2017-10-27 Ｒｏｒ­감마 조절제 Active KR102598775B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
US62/413,907 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (2)

Publication Number Publication Date
KR20190096979A KR20190096979A (ko) 2019-08-20
KR102598775B1 true KR102598775B1 (ko) 2023-11-03

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015082A Active KR102598775B1 (ko) 2016-10-27 2017-10-27 Ｒｏｒ­감마 조절제

Country Status (14)

Country Link
US (5) US10905687B2 (https=)
EP (1) EP3532062B1 (https=)
JP (1) JP7027437B2 (https=)
KR (1) KR102598775B1 (https=)
CN (1) CN110139652B (https=)
AU (1) AU2017348345B2 (https=)
BR (1) BR112019008548A2 (https=)
CA (1) CA3042080A1 (https=)
ES (1) ES2928904T3 (https=)
IL (1) IL266261B (https=)
MX (1) MX392163B (https=)
PH (1) PH12019500949A1 (https=)
RU (1) RU2753490C2 (https=)
WO (1) WO2018081558A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008548A2 (pt) 2016-10-27 2019-09-17 Escalier Biosciences Bv moduladores ror-gama
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제
EP4054712A2 (en) * 2019-11-05 2022-09-14 Dermira, Inc Ror gamma t inhibitors and topical uses thereof
CA3186628A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Ror.gamma.t inhibitors and topical uses thereof
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138438A1 (en) 2008-05-15 2009-11-19 N.V. Organon N- (1, 1, 1, 3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) benzyl-n' -arylcarbonylpiperaz ine derivatives
US20140187554A1 (en) * 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
BR112014003704A2 (pt) * 2011-09-19 2017-03-07 Eth Zuerich moduladores ror gama
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
WO2016145298A1 (en) * 2015-03-12 2016-09-15 The Regents Of The University Of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
BR112019008548A2 (pt) 2016-10-27 2019-09-17 Escalier Biosciences Bv moduladores ror-gama

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138438A1 (en) 2008-05-15 2009-11-19 N.V. Organon N- (1, 1, 1, 3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) benzyl-n' -arylcarbonylpiperaz ine derivatives
US20140187554A1 (en) * 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror

Also Published As

Publication number Publication date
EP3532062A1 (en) 2019-09-04
US20230277527A1 (en) 2023-09-07
US20220175765A1 (en) 2022-06-09
AU2017348345B2 (en) 2022-01-27
WO2018081558A1 (en) 2018-05-03
US20190269674A1 (en) 2019-09-05
CN110139652B (zh) 2022-10-11
PH12019500949A1 (en) 2019-08-05
EP3532062B1 (en) 2022-07-20
KR20190096979A (ko) 2019-08-20
US20210069182A1 (en) 2021-03-11
JP2019535813A (ja) 2019-12-12
CN110139652A (zh) 2019-08-16
ES2928904T3 (es) 2022-11-23
JP7027437B2 (ja) 2022-03-01
MX2019004973A (es) 2019-09-19
EP3532062A4 (en) 2020-04-15
AU2017348345A1 (en) 2019-05-30
IL266261B (en) 2022-07-01
MX392163B (es) 2025-03-21
RU2753490C2 (ru) 2021-08-17
RU2019115059A (ru) 2020-11-27
RU2019115059A3 (https=) 2020-12-18
IL266261A (en) 2019-06-30
CA3042080A1 (en) 2018-05-03
US10905687B2 (en) 2021-02-02
US20240216361A1 (en) 2024-07-04
BR112019008548A2 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
KR102598775B1 (ko) Ｒｏｒ­감마 조절제
CN104284893B (zh) 用于治疗皮肤疾病、病症以及病状的肝x受体(lxr)调节剂
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
KR101732751B1 (ko) Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물
WO2017147161A1 (en) Treatment of dermatological disorders or conditions
JP5746977B2 (ja) 色素沈着予防又は改善剤
CN105683176A (zh) 肝脏x受体(lxr)调节剂
JP7245404B2 (ja) Ｔｒｐｖ１モジュレータ化合物
HK40012522A (en) Ror-gamma modulators
HK40012522B (en) Ror-gamma modulators
CN107759522A (zh) 羧酸类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190524

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201023

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221005

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230803

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231101

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231101

End annual number: 3

Start annual number: 1

PG1601 Publication of registration